Pathogen-Agnostic Sepsis Countermeasures

The contract centers on the research and prototype development of pathogen-agnostic countermeasures for sepsis, targeting treatments or diagnostics effective against multiple infectious agents including Pseudomonas aeruginosa and Shigella. This initiative seeks to identify novel therapeutic or diagnostic platforms that function independently of the specific causative pathogen, addressing the critical challenge of sepsis management in heterogeneous infection scenarios. The work is funded under a subcontract arrangement by the Defense Health Agency within the Department of Defense, reflecting a strategic focus on advancing military and civilian medical readiness through innovative biomedical solutions. The project is tied to NAICS code 541715, categorizing it under research and development in the physical, engineering, and life sciences. The opportunity was posted on August 7, 2026, with a response deadline of October 30, 2026, and the performance location is designated as Frederick. While no set-aside provisions or point of contact details are provided, the emphasis on broad-spectrum effectiveness underscores the need for scalable, broadly applicable technologies that can rapidly respond to complex, multi-pathogen sepsis cases. The contract aims to accelerate the transition from concept to prototype, prioritizing solutions with the potential for immediate deployment in clinical and operational settings.